1198097-97-0

Basic information

• Product Name: Mirin
• Synonyms: (5Z)-2-Amino-5-[(4-hydroxyphenyl)methylene]-4(5H)-thiazolone
• CAS NO: 1198097-97-0
• Molecular Formula: C₁₀H₈N₂O₂S
• Molecular Weight: 220.24772
• Mol File: 1198097-97-0.mol

Chemical Properties

• Boiling Point: 441.6±55.0 °C(Predicted)
• Appearance: /
• Density: 1.49±0.1 g/cm3(Predicted)
• Solubility: insoluble in EtOH; insoluble in H2O; ≥9.3 mg/mL in DMSO
• PKA: 8.70±0.30(Predicted)
• CAS DataBase Reference: Mirin(CAS DataBase Reference)
• NIST Chemistry Reference: Mirin(1198097-97-0)
• EPA Substance Registry System: Mirin(1198097-97-0)

Safety Data

• Hazardous Substances Data: 1198097-97-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Mirin is used as a therapeutic agent for its ability to inhibit the MRN-ATM pathway, which plays a crucial role in DNA repair and cell cycle regulation. By blocking the exonuclease activity of Mre11 and inducing G2 cell cycle arrest, Mirin has potential applications in the treatment of cancer and other diseases characterized by uncontrolled cell proliferation.
Used in Research Applications:
In addition to its potential therapeutic uses, Mirin is also utilized as a research tool to study the mechanisms of DNA repair and cell cycle regulation. Its ability to inhibit the MRN-ATM pathway and induce G2 cell cycle arrest makes it a valuable compound for investigating the roles of these processes in various biological contexts.

Biological Activity

mirin is a potent mrn complex inhibitor. mirin inhibits mre11-associated exonuclease activity, rather than alters dna-binding or mrn complex formation. moreover, mirin prevents mrn-dependent activation of atm in response to dna double-strand breaks, with an ic50 value of 12 μm. the mrn complex acts as a dna damage sensor, responsible for maintaining genome stability during dna replication, promoting homology-dependent dna repair and activating atm. the mrn-atm pathway plays an essential role in sensing and signaling from dna double-strand breaks.1. dupré a, boyer-chatenet l, sattler rm, et al. a forward chemical genetic screen reveals an inhibitor of the mre11-rad50-nbs1 complex. nature chemical biology, 2008, 4(2): 119-125.

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 556-90-1 pseudothiohydantoin 
• 3785-90-8 2-(4-hydroxyphenylmethylene)malononitrile 

Downstream Products

• 1421695-99-9 2-cyclohexylamino-4-oxo-5-(4-hydroxybenzylidene)-Δ²-thiazoline 
• 1421696-05-0 N'-[5-(4-hydroxybenzylidene)-4-oxo-thiazolin-2-yl]cyanoacetichydrazide 
• 81183-01-9 2-morpholino-5-(4-hydroxybenzylidene)-4-oxo-Δ²-thiazoline 
• 1421695-97-7 5-amino-2-(4-hydroxybenzylidene)-7-(4-chlorophenyl)-3-oxo-7H-thiazolo[3,2-a]pyrimidin-6-carbonitrile 
• 81425-22-1 2-piperidino-5-(4-hydroxybenzylidene)-4-oxo-Δ²-thiazoline 
• 1421696-06-1 (Z)-N'-(5-(4-hydroxybenzylidene)-4-oxo-4,5-dihydrothiazol-2-yl)-2-oxo-2H-chromene-3-carbohydrazide 

Relevant articles and documents

A novel synthetic compound, (Z)-5-(3-hydroxy-4-methoxybenzylidene)-2-iminothiazolidin-4-one (MHY773) inhibits mushroom tyrosinase

As part of continued efforts for the development of new tyrosinase inhibitors, (Z)-5-(substituted benzylidene)-2-iminothiazolidin-4-one derivatives (1a – 1l) were rationally synthesized and evaluated for their inhibitory potential in vitro. These compound

New compounds having skin whitening, antioxidant and PPAR activity, and medical use thereof

PURPOSE: A novel compound with skin whitening, antioxidation, and PPAR activation effects, and a medical use thereof are provided to be used for a pharmaceutical composition or a cosmetic product. CONSTITUTION: A compound is denoted by chemical formula 1. A skin whitening composition contains the compound as an active ingredient. An antioxidative composition for preventing or treating oxidative diseases contains the compound of chemical formula 1 as an active ingredient. The oxidative diseases are selected among skin aging, pigmentation, wrinkling, psoriasis, or eczema. The composition prevents or treats diseases which are regulated by PPAR(peroxisome proliferator-activated receptor) activity. The PPAR includes PPAR alpha or PPAR gamma.

NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR

Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPARα and PPARγ activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

Synthesis and spectral characterization of novel thiazolopyridine and pyrimidine derivatives

Novel thiazolo [3,2-a]pyridine and thiazolo[3,2-a]pyrimidine derivatives, pyrazolo[3,4-b]pyrano[2,3-d]thiazole, and coumarin derivatives were synthesized from readily obtainable starting materials such as (Z)-2-ethoxycarbonyl methyl-5-(4-chlorobenzylidene)-2-thiazolidin-4(H)one 3 and (Z)-4-(4- hydroxybenzylidene)-2-imino-2-thiazolidin-4(H)one 11.

Discovery of (Z)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione, a readily available and orally active glitazone for the treatment of concanavalin A-induced acute liver injury of BALB/c mice

A large amount of evidence suggests that monocytes/macrophages infiltration is implicated in a variety of inflammatory diseases including acute liver injury. Monocyte chemoattractant protein 1 (MCP-1) plays a crucial role in the process of macrophages recruitment. We herein presented a small-molecule library and a feasible quick screening method of evaluating potency of inhibition of chemotaxis of RAW264.7 cells stimulated by MCP-1. Fifty-three small molecules were synthesized and screened, and four compounds (2g, 2h, 4f, and 6h) showed inhibitory effects with IC50 values range from 0.72 to 20.47 μM, with compound 4f being the most efficient. Further in vivo studies demonstrated that oral administration of 2g, 2h, 4f, or 6h decreases, most significantly for 4f, the serum levels of alanine aminotransaminase (ALT) and asparate aminotransaminase (AST) in ConA-induced acute livery injury BALB/c mice. Histopathological evaluation liver sections confirmed 4f as a potent, orally active compound for hepatoprotective effects against ConA-induced acute liver injury in BALB/c mice.